SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Galena Biopharma Inc (NASDAQ:GALE), Idera Pharmaceuticals Inc (NASDAQ:IDRA) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) all released their earnings reports for 4Q2015. While GALE and IDRA reported a loss for their 4Q2015, BDSI was able to report a net income, after having a net loss for 4Q2014. Similarly, GALE and BDSI missed analyst expectations, for their EPS, while IDRA was able to beat analyst expectations.

Galena Biopharma reported a total loss of $19.7 million, during its 4Q2015, resulting in a negative EPS of $0.12. As such, the company’s EPS for FY2015 reached -$0.41 or $63.9 million. Mark W. Schwartz, the CEO of GALE, highlighted two upcoming milestones for FY2016. These concern the phase-3 clinical trials of NeuVax. The drug is targeted at the prevention of recurring breast cancer. The announcement resulted in Galena Biopharma Inc (NASDAQ:GALE) shares losing 6.76% of their value, during the March 10 session, to reach a close at $0.886.

Similarly, Idera Pharmaceuticals reported $12 million in losses, during the 4Q2015. The EPS for the quarter stood at -$0.1. For its FY2015, the company had revenues of $249,000 and a loss of $48.6 million, resulting EPS for the year to fall to -$0.42. The highlights of the quarter included the signing of a collaboration and license agreement with GSK. The agreement concerns 3rd Generation Antisense molecules for treatment of renal diseases. Idera Pharmaceuticals Inc (NASDAQ:IDRA) lost 4.81% in terms of its share value, after the announcement, to close at $1.78, at the end of the March 10 trading session.

BioDelivery Sciences was the only one, of the three pharmaceutical companies, to report a net-income for the quarter. The income for 4Q2015 stood at $10.2 million or an EPS of $0.2. The revenue for 4Q2015 stood at $32.2 million. Dr. Mark A. Sirgo, the CEO of BDSI, stated during FY2016, the company would enhance its sales team. This would be assisted by agreement with Tennessee Medicaid and certain government driven initiatives. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) also lost some of its share value, 8.11%, during the March 10 trading session, to close at $3.40.

SHARE
Previous articleSharkreach Inc (OTCMKTS:SHRK) Rolls Out Powerful Campaign Monitoring Tool
Next articleHemispherx BioPharma, Inc (NYSEMKT:HEB) Reviews Ampligen Data with NINDS
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.